EP3533450A4 - Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid - Google Patents
Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid Download PDFInfo
- Publication number
- EP3533450A4 EP3533450A4 EP17864916.6A EP17864916A EP3533450A4 EP 3533450 A4 EP3533450 A4 EP 3533450A4 EP 17864916 A EP17864916 A EP 17864916A EP 3533450 A4 EP3533450 A4 EP 3533450A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- preventing
- pharmaceutical composition
- bile acid
- reperfusion injury
- treating ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
- 206010063837 Reperfusion injury Diseases 0.000 title 1
- 239000003613 bile acid Substances 0.000 title 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/03—Cholic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160143393 | 2016-10-31 | ||
PCT/KR2017/012127 WO2018080276A1 (en) | 2016-10-31 | 2017-10-31 | Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3533450A1 EP3533450A1 (en) | 2019-09-04 |
EP3533450A4 true EP3533450A4 (en) | 2020-06-17 |
Family
ID=62023805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17864916.6A Pending EP3533450A4 (en) | 2016-10-31 | 2017-10-31 | Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid |
Country Status (6)
Country | Link |
---|---|
US (1) | US11185553B2 (en) |
EP (1) | EP3533450A4 (en) |
JP (1) | JP6999664B2 (en) |
KR (1) | KR101999538B1 (en) |
CN (1) | CN110022880B (en) |
WO (1) | WO2018080276A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019509333A (en) * | 2016-08-11 | 2019-04-04 | サムスン ライフ パブリック ウェルフェア ファウンデーションSamsung Life Public Welfare Foundation | Composition for preventing, improving or treating hair loss comprising deoxycholic acid as an active ingredient |
CN114392275A (en) * | 2022-03-04 | 2022-04-26 | 上海中医药大学 | Medical application of bear gall |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014160877A1 (en) * | 2013-03-27 | 2014-10-02 | Metselex, Inc. | Prevention and treatment of kidney damage by bile acids |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU721943B2 (en) | 1996-05-02 | 2000-07-20 | Schering Corporation | Method for treating or preventing ischemia-reperfusion injury |
US8173627B2 (en) | 2004-08-30 | 2012-05-08 | Seo Hong Yoo | Neuroprotective effect of solubilized UDCA in focal ischemic model |
CN1853639A (en) | 2005-04-28 | 2006-11-01 | 中国人民解放军军事医学科学院毒物药物研究所 | Medical use of surface active substance |
CN101732325A (en) * | 2008-11-27 | 2010-06-16 | 中国科学院上海生命科学研究院 | Medicine capable of being used for restoring wound of skin |
KR101064937B1 (en) * | 2009-06-16 | 2011-09-15 | 박상규 | Pharmaceutical composition for preventing or treating restenosis comprising tauroursodeoxycholic acid or its salt |
CA2860676A1 (en) * | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
-
2017
- 2017-10-31 CN CN201780067924.5A patent/CN110022880B/en active Active
- 2017-10-31 WO PCT/KR2017/012127 patent/WO2018080276A1/en unknown
- 2017-10-31 US US16/345,483 patent/US11185553B2/en active Active
- 2017-10-31 JP JP2019523032A patent/JP6999664B2/en active Active
- 2017-10-31 EP EP17864916.6A patent/EP3533450A4/en active Pending
- 2017-10-31 KR KR1020170143696A patent/KR101999538B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014160877A1 (en) * | 2013-03-27 | 2014-10-02 | Metselex, Inc. | Prevention and treatment of kidney damage by bile acids |
Non-Patent Citations (7)
Title |
---|
FALASCA L ET AL: "PROTECTIVE ROLE OF TAUROURSODEOXYCHOLATE DURING HARVESTING AND COLD STORAGE OF HUMAN LIVER A PILOT STUDY IN TRANSPLANT RECIPIENTS", TRANSPLANTATION, WILLIAMS AND WILKINS, GB, vol. 71, no. 9, 15 May 2001 (2001-05-15), pages 1268 - 1276, XP008044995, ISSN: 0041-1337, DOI: 10.1097/00007890-200105150-00015 * |
GAO YH ET AL: "[The protective effect of cholic acid on an in vitro injury model of ischemia-reperfusion in cerebral microvascular endothelial cells].", CHINA JOURNAL OF CHINESE MATERIA MEDICA, vol. 30, no. 12, 1 June 2005 (2005-06-01), pages 930 - 932, XP055691751 * |
GRZEGORZ NOWAK ET AL: "Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats", TRANSPLANT INTERNATIONAL, SPRINGER, BERLIN, DE, vol. 17, no. 12, 1 May 2005 (2005-05-01), pages 804 - 809, XP019324011, ISSN: 1432-2277 * |
LAURENS J. CEULEMANS ET AL: "Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats", PLOS ONE, vol. 12, no. 1, 6 January 2017 (2017-01-06), pages e0169331, XP055691761, DOI: 10.1371/journal.pone.0169331 * |
RAJESH ET AL: "Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K/Akt dependent pathway", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, ACADEMIC PRESS, GB, vol. 39, no. 5, 1 November 2005 (2005-11-01), pages 766 - 776, XP005118778, ISSN: 0022-2828, DOI: 10.1016/J.YJMCC.2005.07.014 * |
RODRIGUES C M P ET AL: "NEUROPROTECTION BY A BILE ACID IN AN ACUTE STROKE MODEL IN THE RAT", JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, NATURE PUBLISHING GROUP, US, vol. 22, no. 4, 1 April 2002 (2002-04-01), pages 463 - 471, XP009064738, ISSN: 0271-678X, DOI: 10.1097/00004647-200204000-00010 * |
See also references of WO2018080276A1 * |
Also Published As
Publication number | Publication date |
---|---|
US11185553B2 (en) | 2021-11-30 |
US20190247406A1 (en) | 2019-08-15 |
KR101999538B1 (en) | 2019-07-12 |
JP2019537591A (en) | 2019-12-26 |
WO2018080276A1 (en) | 2018-05-03 |
JP6999664B2 (en) | 2022-01-18 |
CN110022880B (en) | 2022-04-01 |
CN110022880A (en) | 2019-07-16 |
KR20180048395A (en) | 2018-05-10 |
EP3533450A1 (en) | 2019-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3263135A4 (en) | Pharmaceutical composition for treating cancer comprising microrna as active ingredient | |
EP3431105A4 (en) | Medicinal composition for treating cancer | |
IL256085B (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
EP3552611A4 (en) | Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph | |
EP3533466A4 (en) | Pharmaceutical composition for cancer treatment and/or prevention | |
HK1231416A1 (en) | Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
EP3266317A4 (en) | Composition for preventing, improving or treating neurological disorders, containing osmotin peptide as active ingredient | |
EP3156055A4 (en) | Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof | |
EP3701946A4 (en) | Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound | |
EP3275450A4 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis | |
EP3130353A4 (en) | Graphene nanostructure-based pharmaceutical composition for preventing or treating neurodegenerative diseases | |
EP3556402A4 (en) | Pharmaceutical composition for preventing or treating hepatitis b | |
EP3329929A4 (en) | Pharmaceutical composition for preventing or treating dry eyes | |
EP3556381A4 (en) | Drug for preventing and treating osteoporosis and uses thereof | |
EP3129378A4 (en) | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer | |
EP3391881A4 (en) | Pharmaceutical composition for preventing or treating fatty liver | |
EP3388514A4 (en) | Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases | |
EP3453046A4 (en) | Glutarate compounds for treating ischemia-reperfusion injuries | |
EP3517133A4 (en) | Pharmaceutical composition containing mtor inhibitor for treating macular degeneration | |
EP3375443A4 (en) | Pharmaceutical composition for treating respiratory diseases | |
EP3689355A4 (en) | Pharmaceutical composition for preventing or treating liver cancer | |
EP3148570A4 (en) | Pharmaceutical composition for preventing or treating skin rash | |
GB2579480B (en) | Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient | |
EP3162803A4 (en) | New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient | |
IL280389A (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190527 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200518 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A23L 33/10 20160101ALI20200512BHEP Ipc: A61K 9/48 20060101ALI20200512BHEP Ipc: A61K 31/575 20060101AFI20200512BHEP Ipc: A61P 9/10 20060101ALI20200512BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20221020 |